Evidence map›Paper›PMID 30171268›Full record

ArticleApplied microbiology and biotechnology2018

n-Butanol production in S. cerevisiae: co-ordinate use of endogenous and exogenous pathways.

R Swidah, O Ogunlabi, C M Grant, M P Ashe

Open access · hybridAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

R SwidahDivision of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Michael Smith Building, Oxford Rd., M13 9PT, Manchester, UK.
O OgunlabiDivision of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Michael Smith Building, Oxford Rd., M13 9PT, Manchester, UK.
C M GrantDivision of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Michael Smith Building, Oxford Rd., M13 9PT, Manchester, UK.
M P AsheDivision of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Michael Smith Building, Oxford Rd., M13 9PT, Manchester, UK. mark.p.ashe@manchester.ac.uk.ORCID http://orcid.org/0000-0002-4457-7851
Manchester Academic Health Science Centre · GB

Funding

Biotechnology and Biological Sciences Research Council BB/K002767/1
6 · The paper itself

Abstract

n-Butanol represents a key commodity chemical and holds significant potential as a biofuel. It can be produced naturally by Clostridia species via the ABE pathway. However, butanol production via such systems can be associated with significant drawbacks. Therefore, substantial efforts have been made toward engineering a suitable industrial host for butanol production. For instance, we previously generated a metabolically engineered Saccharomyces cerevisiae strain that produces ~300 mg/L butanol from combined endogenous and exogenous pathways. In this current study, the endogenous and exogenous pathways of butanol production were further characterised, and their relative contribution to the overall butanol titre was assessed. Deletion of any single component of the exogenous ABE pathway was sufficient to significantly reduce butanol production. Further evidence for a major contribution from the ABE pathway came with the discovery that specific yeast deletion mutants only affected butanol production from this pathway and had a significant impact on butanol levels. In previous studies, the threonine-based ketoacid (TBK) pathway has been proposed to explain endogenous butanol synthesis in ADH1 mutants. However, we find that key mutants in this pathway have little impact on endogenous butanol production; hence, this pathway does not explain endogenous butanol production in our strains. Instead, endogenous butanol production appears to rely on glycine metabolism via an α-ketovalerate intermediate. Indeed, yeast cells can utilise α-ketovalerate as a supplement to generate high butanol titres (> 2 g/L). The future characterisation and optimisation of the enzymatic activities required for this pathway provides an exciting area in the generation of robust butanol production strategies.

Indexed as

1-ButanolBiofuelsBiosynthetic PathwaysMetabolic EngineeringSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSequence Deletion1-ButanolBiofuelsSaccharomyces cerevisiae ProteinsEndogenous pathwayExogenous pathwayMetabolic engineeringn-butanolS. cerevisiae

Identifiers

PMID30171268
PMCPMC6208969
OpenAlexW2888293332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.